环孢素治疗后葡萄膜炎的经验。

Experience with cyclosporine in endogenous uveitis posterior.

作者信息

Hesselink D A, Baarsma G S, Kuijpers R W A M, van Hagen P M

机构信息

Department of Internal Medicine, Renal Transplant Unit, Erasmus Medical Center, Rotterdam, The Netherlands.

出版信息

Transplant Proc. 2004 Mar;36(2 Suppl):372S-377S. doi: 10.1016/j.transproceed.2004.01.003.

DOI:10.1016/j.transproceed.2004.01.003

PMID:15041371

Abstract

Treatment with cyclosporine (CsA) has considerably improved the visual prognosis of patients suffering from endogenous posterior uveitis (EPU). However, the therapeutic benefits of CsA are partially outweighed by its many side effects, most notably nephrotoxicity and hypertension. Low-dose CsA regimens have reduced toxicity but have not been able to completely eliminate this problem. New therapeutic approaches, such as anti-tumor necrosis factor alpha treatment or immunosuppression with drugs including tacrolimus, sirolimus, and interleukin-2 receptor antibodies, are currently under evaluation. Hopefully such strategies will further reduce the morbidity of EPU and minimize the adverse effects associated with conventional therapies.

摘要

用环孢素（CsA）治疗已显著改善了内因性后葡萄膜炎（EPU）患者的视力预后。然而，CsA的治疗益处部分被其诸多副作用所抵消，最显著的是肾毒性和高血压。低剂量CsA方案已降低了毒性，但未能完全消除这一问题。包括抗肿瘤坏死因子α治疗或使用他克莫司、西罗莫司和白细胞介素-2受体抗体等药物进行免疫抑制在内的新治疗方法目前正在评估中。有望此类策略将进一步降低EPU的发病率，并使与传统疗法相关的不良反应最小化。